Today's Research Reports on Trending Tickers: Biogen and Biocept
NEW YORK, NY / ACCESSWIRE / December 19, 2018 / Shares of Biogen were continuing to slump on Tuesday after a slight recovery on Monday from last week’s descent. The company and Alkermes plc recently announced that Alkermes has submitted a New Drug Application to the FDA for diroximel fumarate (BIIB098). Shares of Biocept were soaring on high volume on news that the company has entered into a Software License and Laboratory Data Supply Agreement with Prognos, Inc.
The Market Edge Initiates Coverage on:
Biogen Inc.
https://marketedgereport.com/report/BIIB/
Biocept, Inc.
https://marketedgereport.com/report/BIOC/
Biogen Inc. shares closed down 5.86% on nearly 3 million shares traded yesterday. The Company along with Alkermes plc announced that the latter has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for diroximel fumarate (BIIB098), a novel oral fumarate in development for the treatment of relapsing forms of multiple sclerosis (MS). “The filing of diroximel fumarate by our partners at Alkermes demonstrates our enduring commitment to people living with MS and builds on our established track record as a leader in the industry,” remarked Michael Ehlers, M.D., Ph.D., executive vice president, research & development at Biogen. “MS is a heterogeneous disease, and while there are a number of approved therapies available today, continued treatment advances remain an important priority.” Shares of the stock were falling for the past week and continued falling on Monday and Tuesday after seeing some recovery in intra-day trading on Monday.
Access The Market Edge's Biogen Inc. Research Report:
https://marketedgereport.com/report/BIIB/
Biocept, Inc. shares closed 66.28% on Tuesday with around 23.6 million shares traded. Average trading volume for the stock is only around 215,000 shares. The commercial provider of liquid biopsy tests has entered into a Software License and Laboratory Data Supply Agreement with Prognos, Inc., an innovator in predicting disease by applying artificial intelligence (AI) to clinical laboratory diagnostics. As stated in the press release, as part of the agreement, "Biocept will supply de-identified data from its liquid biopsy testing to Prognos, which will leverage its AI capabilities to help its pharmaceutical clients ensure that the right patients receive the right therapies. Biocept will utilize Prognos' proprietary Opal® de-identification software in accordance with the Health Insurance Portability and Accountability Act of 1996 to collect and transmit the data to Prognos." CEO of Biocept, Michael Nall, commented, "With over 16,000 patient samples and more than 60,000 total Target Selector™ tests performed, we are positioned to continue generating important clinical data that, once de-identified and aggregated, can be valuable to the scientific, medical and healthcare delivery communities. We are looking forward to working with Prognos to leverage the data produced by our molecular diagnostic platform and the ability to generate additional revenue for our business."
Access The Market Edge's Biocept, Inc. Research Report:
https://marketedgereport.com/report/BIOC/
Our Actionable Research on Biogen Inc. (NASDAQ: BIIB) and Biocept, Inc. (NASDAQ: BIOC) can be downloaded free of charge at The Market Edge.
The Market Edge
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
The Market Edge has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of MarketEdgeReport.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. MarketEdgeReport.com is neither a registeredbroker dealernor a registered investment advisor. For more information please read our full disclaimer at www.marketedgereport.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
The Market Edge, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: The Market Edge
